Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC-2-Globo H-KLH conjugate vaccine
- Development stage
- Phase 1
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MUC-2-Globo H-KLH conjugate vaccine is a therapeutic cancer vaccine that combines the Globo H antigen (a tumor-associated carbohydrate antigen) with keyhole limpet hemocyanin (KLH) as a carrier protein. It is designed to induce an immune response against cancer cells expressing Globo H. The vaccine works by stimulating the production of antibodies against Globo H-expressing tumor cells, which can lead to complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
- Other names
- MUC-2-Globo H-KLH conjugate vaccineMUC2-Globo H-KLH conjugate vaccineMUC 2-Globo H-KLH conjugate vaccineBivalent MUC-2-Globo H-KLH vaccine
02
Targets
Globo-H
Beyond the preview
Go deeper on MUC-2-Globo H-KLH conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC-2-Globo H-KLH conjugate vaccine.